Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ProKidney Corp. - Class A Ordinary Shares
(NQ:
PROK
)
1.740
+0.090 (+5.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ProKidney Corp. - Class A Ordinary Shares
< Previous
1
2
Next >
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
November 12, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
November 05, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
October 14, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in the UBS Virtual Organ Restoration Day
October 09, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
September 03, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 27, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
August 09, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
June 17, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
June 11, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
June 10, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
June 10, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
May 21, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
May 10, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
March 25, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in Jefferies Biotech on the Bay Summit
February 29, 2024
From
ProKidney
Via
GlobeNewswire
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
November 30, 2023
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
November 21, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Reports Third Quarter Financial Results
November 14, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
November 13, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
October 30, 2023
Total of 6 abstracts accepted for publication in Kidney Week 2023 program
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
September 05, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
August 10, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
July 18, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
July 17, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
June 13, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
June 01, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
May 11, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney to Present at the BofA Securities Health Care Conference 2023
May 04, 2023
From
ProKidney
Via
GlobeNewswire
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
March 28, 2023
From
ProKidney
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.